Pharma news

Series of FDA’s Approvals in ALS Drdeservesymphoma Space; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises

FDA’s Go-Ahead to Amylyx New Drug Application for ALS Drug  Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).  A few months ago, the company had decided to file …

Series of FDA’s Approvals in ALS Drdeservesymphoma Space; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Read More »

ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System

ADARx bags USD 75 Million to advance its RNA tech pipeline ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics, announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series B. Sirona Capital united this financing as well as …

ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System Read More »

Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indications.  Under their deal Genentech will work with Adaptimmune to develop …

Roche inks $3B deal; Owlstone raises $58M; FDA approves OCS heart system; Google, Mayo Clinic build brain-mapping AI algorithm Read More »

Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ’s HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune’s Alzheimer’s Antibody Drug

Pfizer’s RSV Vaccine enters in the late-stage of clinical trials  As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a critical late-stage study of its experimental vaccine against a severe version of a cold virus that may cause pneumonia and death in the young …

Pfizer’s RSV Vaccine; Forte Biosciences’ Atopic Dermatitis Asset; Bone Therapeutics’ Osteoarthritis Programme; JandJ’s HIV Vaccine Trial; Versanis Bio $70 M Series A Financing; AC Immune’s Alzheimer’s Antibody Drug Read More »

Ascendis’s SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin’s Voxzogo; Zimmer-Canary’s Smart Knee Implant; COVID-19 impact on Solid Organ Transplants

FDA’s Green Flag to Ascendis’s Once-Weekly SKYTROFA for Treatment of Pediatric Growth Hormone Deficiency For the treatment of growth failure due to deficiency of growth hormones, the USFDA approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd) for children of one year and older suffering from an improper secretion of endogenous growth hormone (GH). Growth Hormone Deficiency, commonly known …

Ascendis’s SKYTROFA; MicroTransponder’s VNS System (Vivistim); BioMarin’s Voxzogo; Zimmer-Canary’s Smart Knee Implant; COVID-19 impact on Solid Organ Transplants Read More »

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Shape Therapeutics inks gene therapy deal with Roche worth up to USD 3 Billion Seattle biotech firm Shape Therapeutics has signed a deal potentially exceeding USD 3 billion with pharma giant Roche to bolster the development of gene therapies for Alzheimer’s and Parkinson’s disease. Shape’s RNA editing technologies can modify the RNA sequence, which makes …

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine Read More »

AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi

AstraZeneca’s Newly Occupied Alexion Hits Rock Bottom After Ultomiris (Ravulizumab) Fails to Show Efficacy in Patients with Amyotrophic Lateral Sclerosis AstraZeneca’s 39 billion USD complete acquisition of Alexion took over just a few months back. Unpleasant news strike hard for their first deal in the rare neurodegenerative disease domain. Alexion focuses on finding medications for …

AstraZeneca’s Ultomiris; HebaBiz’s Siroquine; Pfizer’s XELJANZ; Bristol Myers Squibb’s Opdivo; and Masimo’s PVi Read More »

Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents’ DrugSorb-ATR; Fujifilm-Lunit collaboration

Boston Scientific starts recruitment for randomized controlled trials for the EkoSonic Endovascular System On August 04, 2021, Boston Scientific Corporation started the enrolment in the HI-PEITHO clinical trial, which is a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium and the University Medical Center of the Johannes Gutenberg University of Mainz comparing …

Boston Scientific’s EkoSonic; FDA clearance for EXALT; Kestra Medical’s ASSURE; ZOLL Next-Generation remedē system; CytoSorbents’ DrugSorb-ATR; Fujifilm-Lunit collaboration Read More »

FDA approval to Keytruda and Lenvima; FibroGen’s Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palovarotene; Jazz Pharma’s Xywav; Seagen-RemeGen’s Cancer Medicine

FDA’s Green Flag to Keytruda and Lenvima combination by Merck and Eisai for Advanced renal cell carcinoma (RCC) The FDA approved the combination of Keytruda and Lenvima produced by Merck and Eisai, as a first-line treatment of adult patients with advanced renal cell carcinoma (RCC). The efficacy and safety results were produced from a broad …

FDA approval to Keytruda and Lenvima; FibroGen’s Roxadustat; Pfizer’s TICOVAC; Ipsen’s Palovarotene; Jazz Pharma’s Xywav; Seagen-RemeGen’s Cancer Medicine Read More »

LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drugVisus raises $20M

LQT Therapeutics secures USD 19 Million to tackle heart diseases with Sanofi compounds LQT Therapeutics intends to tackle debilitating heart arrhythmias with limited interventions, and investors are planting a seed in the biotech’s heart with USD 19 million.  The two-year-old Canadian biotech will utilize series A to bring a lineup of SGK1 inhibitors through phase …

LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drugVisus raises $20M Read More »

Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea’s Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer

FDA Approves Keytruda in Both Adjuvant and Neoadjuvant Setting in High-Risk Early-Stage TNBC In July 2021, the US FDA approved pembrolizumab (Keytruda) for high-risk, early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and then continued as a single agent as adjuvant treatment after surgery. This approval was based on Phase III …

Merck’s Keytruda Approval; Abbvie’s Venetoclax; Aprea’s Eprenetapopt; CRL to Incyte’s Retifanlimab; Keytruda/Lenvima for Endometrial Cancer Read More »

Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation

Sanofi bets USD 3.2 Billion on mRNA with a deal to acquire Translate Bio Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acquire …

Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Read More »

Nevro’s Spinal Cord Stimulation; Boston’s PINNACLE FLX; NuVasive’s Modulus ALIF; J&J’s VERITAS Vision System; Medtronic’s DCB Catheter; AngelMed’s Heart Attack Warning System

Nevro Received FDA Approval of its 10 kHz High-Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy On July 19, 2021, Nevro Corp. received approval for its Senza System, Nevro’s unique 10 kHz stimulation, to treat chronic pain associated with Painful Diabetic Neuropathy (PDN). The company plans to initiate …

Nevro’s Spinal Cord Stimulation; Boston’s PINNACLE FLX; NuVasive’s Modulus ALIF; J&J’s VERITAS Vision System; Medtronic’s DCB Catheter; AngelMed’s Heart Attack Warning System Read More »

Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal

Teneobio and its next-gen cancer work acquired by Amgen  Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on …

Amgen acquires Teneobio for $2.5B; Signifier scores $35M; Biogen-Ionis’ drug meets a goal; AbbVie hits go on $1B re-upped Calico deal Read More »

Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial

Alzheimer’s Association International Conference (AAIC) 2021 Opens With Thrilling Details of Pharmas and Powerful Therapeutic Discoveries  The most awaited Alzheimer’s Association International Conference 2021 (AAIC) commenced yesterday on July 26th, 2021 in Denver, Colorado, which was presented both virtually as well as in person. It will be held till 30th July 2021.  Various Active Pharmaceuticals …

Commencement of AAIC; GSK’s Shingles Vaccine Expanded Approval; Pfizer/ BioNtech Agreement with Biovac; Another Failure in Ulcerative Colitis Trial Read More »

BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M

BlueRock Therapeutics secures FDA fast track for Parkinson’s disease cell therapy BlueRock, a Bayer subsidiary, is currently assessing the pluripotent stem cell-derived dopaminergic neuron therapy in a phase 1 study. This early-stage trial is set to enroll ten patients across the US and Canada, with its primary aim to evaluate the safety and tolerability of …

BlueRock secures FDA fast track; Omniscient rakes in $29M; Neuspera’s nerve implant gets a $65M boost Rivus’ therapy nabs $35M Read More »

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer

Beam adds to drug delivery stable with USD 120 Million GuideTx buy Beam Therapeutics has taken over a startup whose technology could proffer the biotech’s genetic medicines to more tissues in the body, widening the potential to approach more diseases. Beam announced that it paid USD 120 million upfront to acquire Guide Therapeutics in an …

Beam makes USD 120M bet; GRAIL and Quest announce the collaboration; Brain organoids mimic infant’s brains; Improvement in T cells to kill cancer Read More »

Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the BB305 lentiviral vector is linked to AML and MDS cases.  …

Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Read More »

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis

Verily collaborates with Janssen to launch COVID-19 immune response study Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes.  The study will be launched by Verily’s Project Baseline testing program and intends to collect …

Verily – Janssen collaboration; Enhancing the response in pancreatic cancer; Avrobio gene therapy eradicates toxic substrate; Gut microbiome responsible for Multiple Sclerosis Read More »

Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs

Plaque psoriasis drug outshines the competition in phase III trial Bristol Myers Squibb’s psoriasis drug, the TYK2 inhibitor outshone placebo and Amgen’s Otezla in a second phase 3 study, setting discussions with regulators. The study, known as POETYK PSO-2, trialled the drug, deucravacitinib, against placebo and Otezla in 1,020 patients with moderate to severe plaque …

Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Read More »

Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials

Nirogy Therapeutics rises with USD 16.5 Million to target metabolite transporters Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules for targeting cellular transporters, announced the closing of a USD 16.5 million Series A financing.  Nirogy plans to use the proceeds to improve its drug discovery platform for generating a pipeline of small-molecule …

Nirogy rises with $16.5M; Iterum presents a new drug application to FDA; Gut Bacteria proffer insight into molecules protection; TScan adds another $100M for cancer trials Read More »

Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline.

Unshackling the TP53 in leukaemia with a novel combination approach. Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. However, they might be useful if they were combined.   Researchers at the Sanford Burnham Prebys Medical Discovery Institute …

Unshackling TP53 in leukaemia with a novel combo; Merus receives funds for cancer research pact; Vera Therapeutics bags $80M; Gritstone appends COVID-19 to the pipeline. Read More »

Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate

Gilead and Vir Biotechnology Establish Clinical Collaboration  Gilead Sciences, Inc. and Vir Biotechnology, Inc. announced that the companies have entered into a clinical collaboration to assess novel therapeutic combination strategies to develop a functional remedy for chronic hepatitis B virus (HBV). The companies schedule to initiate a Phase 2 trial assessing combination therapy for both …

Gilead and Vir collaborate; Tessera scores $230M; Teladoc & Dexcom bring CGM Tech; Verve unveils lead candidate Read More »

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The Series B round begins as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and pushes a first-in-class KRAS asset through lead …

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Read More »

Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis

Improving cancer immunotherapy by recovering a warning system Cancer cells, most of the time, develop tactics to elude the immune system. A research team that is led by scientists at Memorial Sloan Kettering Cancer Center has recognized one such mechanism, and it believes aiming it with drugs could potentially enhance responses to immuno-oncology treatments. A …

Improving cancer immunotherapy; Senseonics’ Eversense delayed; FDA acknowledges Alkermes’ Resubmission; 3D breast ultrasound improves diagnosis Read More »

NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors

NIH awards USD 107 Million for radical COVID-19 testing tech  The National Institutes of Health (NIH) awarded over USD 107 million for radical approaches to testing for COVID-19 and tracing the spread of the disease, including cutting-edge technologies, which could make daily coronavirus testing less interfering. dThis comprises nontraditional and repurposed technologies to address the …

NIH awards $107M for COVID-19 testing tech; GSK secures rights; Roche’s bispecific matches Eylea; Research Updates in Leukemia, solid tumors Read More »

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3

AstraZeneca’s COVID-19 vaccine data suggest single-dose efficacy The full data from late-phase trials of AstraZeneca’s COVID-19 vaccine have pointed to the potential for AZD1222 to work after a single dose and limit asymptomatic cases; however, missed main questions regarding the efficacy of the candidate. The results that were posted in The Lancet restate the headline …

AstraZeneca’s COVID-19 vaccine; Type 1 diabetes research updates; FDA nod to Zebra’s X-ray modelling AI; UniQure/CSL haemophilia B gene therapy curbs bleeding in phase 3 Read More »

KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH

KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market.  As its lead program, KaliVir is developing VET2-L2 leveraging its unique technology …

KaliVir, Astellas licensing deal; AbCellera’s IPO; Bayer CAR-T Cell therapy collab with Atara; Aligos, Merck together against NASH Read More »

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study

Roche receives FDA authorization for the quantitative COVID-19 antibody test Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. The company anticipates the test can aid in tracking the success of vaccines and …

Roche’s quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Read More »

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors in mice Several viruses have a natural ability to eliminate cancer; however translating them into treatments has proven difficult, partly due to the immune system tends to kill them before they can reach cancer cells. Researchers from Emory and Case Western Reserve state they have …

Cancer-killing virus flees immune destruction and attacks metastatic lung tumors; Urovant’s vibegron fails trial; Genmab discards antibody-drug conjugate; Polyphor picks up $3.3M for inhaled antibiotic Read More »

FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

FDA rejects BioMarin’s gene therapy and Gilead’s filgotinib over concerns The FDA refused to approve BioMarin’s hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) letter, which could cause a significant delay for …

FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes Read More »

HETERO Walk Ins for Freshers And Experienced Production QC QA Engineering B Pharm BSc MSc B Com B A Inter Diploma And ITI Candidates on 15th And 16th Aug 2020

 HETERO – Walk-Ins on 15th & 16th Aug’ 2020 Department:  Production, QC, QA, Engineering Qualification:  B.Pharm, B.Sc, M.Sc, B.Com, B.A, Inter, Diploma & ITI Candidates Experience: 0 to 3 yrs ( for Freshers & Experienced) Visit above links for more information

Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive …

Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV’s peanut allergy patch; Combating COVID-19 with decoy target Read More »

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal’s total near to USD 2 billion. The drug, UCB0107, is designed to …

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures Read More »

AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid’s DMD gene therapy trial

AZ, Daiichi put their trust into TROP2-based drugs, inks an oncology deal to together develop and commercialize DS-1062 AstraZeneca has inked an oncology deal with Daiichi Sankyo to jointly develop and commercialize an antibody-drug conjugate DS-1062 (trastuzumab deruxtecan), worldwide except in Japan. Daiichi holds exclusive rights to the drug in Japan. Daiichi’s DS-1062, a trophoblast …

AZ, Daiichi inks an oncology deal; Moderna begins Phase III trial of its COVID-19 vaccine; No good news for Solid’s DMD gene therapy trial Read More »

AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership

AstraZeneca demonstrates positive early results from its trial evaluating COVID-19 vaccine-AZD1222 In a frenzied race to find a global cure for COVID-19, several pharma players are testing waters and presenting results from clinical studies evaluating their potential candidates. Not long after, Moderna, a US biotech, presented early results of its vaccine candidate m1273, drugmaker AstraZeneca …

AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Read More »

Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update

Orchard licenses the gene therapy technology from GlaxoSmithKline  Orchard Therapeutics has permitted lentiviral stable cell line technology from GlaxoSmithKline for its use in hematopoietic stem cell gene therapies. GSK filed for patents on the tech before selling its rare disease gene therapy portfolio to Orchard in the year 2018. The use of lentiviral vectors for …

Orchard licenses gene therapy tech from GSK; Glympse raises $46M; FDA voted to recommend Terlipressin; Breast Cancer research update Read More »

Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates

Sanofi licenses NK cells of Kiadis to boost the efficacy  Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclisa. The deal worth of USD 986 million gives the global rights to Sanofi for therapies that could lessen an efficacy-limiting shortcoming of anti-CD38 antibodies. …

Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates

Read More »

Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies

Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19.   Regeneron is running two trials simultaneously, one for prevention and other for treatment, with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). Phase III trial is studying if the cocktail antibody has the pre-emptive potential and can …

Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies

Read More »